EGFR and glioblastoma: In the phase II study of Depatux-M alone and with temozolomide vs. temozolomide or lomustine in recurrent EGFR amplified GBM (Intellance 2/EORTC 1410), patients with EGFR amplified GBM at first recurrence following standard chemoradiation were randomised to receive either Depatux-M alone, in combination with temozolomide (TMZ) or standard of care chemotherapy (lomustine/TMZ) [94].